Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease

Lilly

Status and phase: Completed; Phase 2

Conditions: Alzheimer's Disease

Treatments: Drug: LY451395

Study type: Interventional

Funder types: Industry

Identifiers

NCT00051909

H6N-MC-LEAM

6764

Details and patient eligibility

About

Study of an investigational medication for the treatment of Alzheimer's Disease in patients who are not taking Aricept, Reminyl, Exelon.

Sex: All

Ages: 50+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Must have a clinical diagnosis of Alzheimer's Disease
• Must be at least 50 years of age
• Must fluently read and speak English
• Must have a reliable caregiver

Exclusion criteria

• Has serious health problems other than Alzheimer's Disease
• Cannot swallow whole pills
• Has had a menstrual period in the last two years
• Takes insulin for diabetes
• Has taken Aricept, Reminyl, or Exelon in the last 5 weeks

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind